Enhancement of endocannabinoid signaling and the pharmacotherapy of depression.
Cannabinoids are well known modulators of mood and emotional behavior. Current research supports a role for endocannabinoid signaling in the treatment of depression. Changes in levels of the cannabinoid CB(1) receptor or the endogenous CB(1) receptor ligands, anandamide and 2-AG, are observed both in humans suffering from depression and in animal models of depression, and experimental manipulation of CB(1) receptor signaling has also been shown to affect emotional reactivity in rodents. Importantly, inhibitors of anandamide inactivation have demonstrated efficacy in enhancing stress-coping and mood-related behavior. This article will review these areas of research, highlighting the potential of endocannabinoid metabolism modulators as therapeutics for the treatment of depression.
Mangieri
Regina A
RA
Department of Pharmacology and Center for Drug Discovery, The University of California, Irvine, CA 92697, USA.
Piomelli
Daniele
D
D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use*; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism*; D003863:Depression / Q000188:drug therapy*; D063388:Endocannabinoids; D006801:Humans; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism; D015398:Signal Transduction
D000928:Antidepressive Agents; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D043884:Receptor, Cannabinoid, CB1